A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Phase of Trial: Phase II/III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Treprostinil (Primary)
- Indications Emphysema; Interstitial lung diseases; Pulmonary fibrosis; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms INCREASE
- Sponsors United Therapeutics Corporation
- 05 Jul 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated